Mounjaro® and diarrhea

The diarrhea row, dose by dose

Table 1 of the US label draws on SURPASS-1, where tirzepatide was the only diabetes medicine, and SURPASS-5, where it was added to basal insulin with or without metformin; 718 adults took tirzepatide for an average of 36.6 weeks ^[1]. The European and Canadian documents print the same pool unrounded, and Canada adds a larger seven-trial pool. Europe also reports a weight-management study in people without diabetes, because in the EU tirzepatide carries the Mounjaro® name for that use too ^[3][4].

One small inconsistency is worth knowing about: for 15 mg in the same placebo-controlled pool, the European document prints 16.2% and the Canadian one 16.6%. We show each as published.

Reading the placebo column

Placebo matters more for diarrhea than for most rows in the table. Almost one in ten people taking a dummy injection in the diabetes trials still reported loose stools, so the excess on Mounjaro® is a few percentage points at 5 mg and 10 mg and clearer at 15 mg ^[1]. For nausea, by contrast, placebo sat at 4% ^[1].

The picture shifts in the European weight-management study, where placebo diarrhea was lower and tirzepatide figures were higher, roughly a threefold difference ^[3]. The European Medicines Agency places diarrhea in its “very common” band, meaning at least 1 person in 10 ^[3]. The US label prints no separate diarrhea figure for the SURPASS-CVOT heart trial or the pediatric trial and does not name diarrhea among the reactions that differed in either ^[1].

How tirzepatide compares in trial reviews

A meta-analysis of seven trials in type 2 diabetes found diarrhea more likely on tirzepatide 15 mg than on placebo, with odds about 3.3 times higher. Against GLP-1 receptor agonists, the odds of stomach events were similar except for diarrhea on the 10 mg dose, which was somewhat higher ^[5]. A second meta-analysis reached a similar view: diarrhea was more frequent than with insulin at all doses, and higher than with GLP-1 receptor agonists at 10 mg ^[6].

A pooled analysis of SURPASS-1 to -5 reported diarrhea in 12% to 22% of people on tirzepatide, mostly transient and mild to moderate. Weight loss did not depend on whether people had nausea, vomiting or diarrhea; several of its authors work for the manufacturer ^[7].

Gas, bloating and other bowel changes

Under its table, the US label lists stomach and bowel reactions that were more frequent on Mounjaro® than on placebo but stayed under the 5% threshold. Flatulence was reported by 0% on placebo and by 1.3%, 2.5% and 2.9% on 5, 10 and 15 mg; a swollen or bloated belly by 0.4% on placebo and 0.4%, 2.9% and 0.8% on the three doses ^[1]. In the Canadian seven-trial pool, flatulence ran at 2.0% to 3.1% and abdominal distension at 2.9% to 3.4% ^[4].

Reports collected after approval, without frequencies, include ileus and intestinal obstruction ^[1]. These are not diarrhea, but they are a reason to mention any sudden change in bowel habit that comes with pain, swelling or vomiting.

Why it happens: what is and is not known

What the labels support: diarrhea gathers around dose increases and becomes less frequent afterwards, and the step-up of at least four weeks per dose exists to reduce stomach and bowel reactions ^[1][3]. The labels describe slower stomach emptying, strongest after the first dose, but they do not state a mechanism for diarrhea ^[1].

What is unmeasured: why a medicine that slows the stomach can loosen stools in some people and constipate others is not explained in any of the product information we read. We found no tirzepatide-specific study that settles it.

General background: the NIH lists side effects of medicines among the common causes of sudden diarrhea, together with infections and food poisoning ^[8].

Other causes, including other diabetes medicines

Many people taking Mounjaro® also take metformin, and MedlinePlus lists diarrhea, nausea, stomach discomfort and gas among metformin’s side effects ^[10]. The NIH adds antibiotics, antacids containing magnesium and the sugar alcohols in some sugar-free sweets, gum and liquid medicines as possible triggers, along with infections, food poisoning and food intolerances ^[8].

A stomach bug that others around you also have, a new food, a trip or a new medicine all point away from tirzepatide. Diarrhea that lasts for weeks has a longer list of causes, including infections, intolerances and digestive conditions, and is worth investigating rather than attributing to the injection ^[8].

Fluids, kidneys and metformin

The US label reports acute kidney injury after approval, sometimes needing dialysis, mostly in people dehydrated by stomach reactions, and asks for kidney monitoring in those reactions, especially at the start and after increases ^[1]. For people with reduced kidney function, no dose change is needed because tirzepatide levels are unaffected, but kidney function should be checked when treatment starts or increases if they report severe stomach or bowel reactions ^[1]. Canada does not recommend Mounjaro® in end-stage kidney disease because experience there is very limited ^[4].

Metformin adds its own caution. MedlinePlus asks people taking it to tell their doctor about severe diarrhea or vomiting, or drinking much less than usual, because metformin may need to be paused until they recover ^[10]. The European information also flags electrolyte disturbances alongside dehydration ^[3].

What may help

The Medication Guide’s practical point is that drinking fluids lowers the chance of dehydration ^[2]. MedlinePlus self-care advice for diarrhea adds more, without replacing what your prescriber tells you ^[9]:

• Keep up clear fluids through the day, with water as the first choice, and drink extra each time you have a loose stool ^[9].
• Eat small meals spread through the day rather than three large ones, and include some salty foods and foods with potassium, such as bananas or potatoes; check with your provider first if you have significant kidney disease ^[9].
• For a while, avoid fried and greasy food, vegetables that cause gas, caffeine, alcohol and fizzy drinks, and cut back on dairy if it seems to make things worse ^[9].
• Ask your provider before taking a medicine to slow diarrhea, a fibre supplement or sports drinks; because tirzepatide slows stomach emptying, it can also change how tablets are absorbed ^[1][9].
• If dehydration seems to be starting, MedlinePlus suggests sipping water or drinks with electrolytes and warns against salt tablets ^[11].

What to note for your prescriber

Counts are the most useful: loose stools per day, the day and time it began, how many days after your injection that was, and how long it lasted. Note any other medicines you take, especially metformin or recent antibiotics, how much you drank and whether vomiting, fever or stomach pain came with it. Your prescriber decides whether any change is needed; the European leaflet asks you not to change your dose on your own ^[3].

Mounjaro® is a registered trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.